Close Menu

NEW YORK (GenomeWeb News) – Investment firm Mizuho Securities has initiated coverage of Complete Genomics with an Outperform rating and a 12-month price target of $10.

In a research report issued Wednesday after the close of the market analyst Peter Lawson estimated 2011 revenue at $25.3 million resulting in adjusted loss per share of $2.08, and 2012 revenue at $38.5 million with an adjusted loss per share of $1.78.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Sep
24
Sponsored by
ArcherDX

NTRK fusions are oncogenic drivers in a variety of tumors.